SCHEMBL2393255

SCHEMBL2393255

C[N+]1(CCCCCCCCC[N+]2(C)CCCC2)CCCC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BBOX1 O75936 2/20 0.56
LMNA P02545 4/20 0.53
APOBEC3A P31941 2/20 0.53
APOBEC3G Q9HC16 2/20 0.53
KMT2A Q03164 2/20 0.53
CYP3A4 P08684 1/20 0.53
TSHR P16473 1/20 0.53
TDP1 Q9NUW8 1/20 0.53
BLM P54132 1/20 0.53
PMP22 Q01453 1/20 0.53
KDM4E B2RXH2 1/20 0.48
CTDSP1 Q9GZU7 1/20 0.43
CHRM2 P08172 1/20 0.40
CHRM4 P08173 1/20 0.40
CHRM5 P08912 1/20 0.40
CHRM1 P11229 1/20 0.40
CHRM3 P20309 1/20 0.40
GNAI3 P08754 1/20 0.39
GNAO1 P09471 1/20 0.39
GNAI1 P63096 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3674134 1.00 BBOX1 (0.56) BBOX1LMNAAPOBEC3AAPOBEC3GKMT2A
SCHEMBL12638424 1.00 BBOX1 (0.56) BBOX1LMNAAPOBEC3AAPOBEC3GKMT2A
SCHEMBL7593954 1.00 BBOX1 (0.56) BBOX1LMNAAPOBEC3AAPOBEC3GKMT2A
Pentolinium SCHEMBL210048 1.00 BBOX1 (0.56) BBOX1LMNAAPOBEC3AAPOBEC3GKMT2A
SCHEMBL2158184 1.00 BBOX1 (0.56) BBOX1LMNAAPOBEC3AAPOBEC3GKMT2A
Pentolinium SCHEMBL7605988 0.97 BBOX1 (0.54) BBOX1LMNAAPOBEC3AAPOBEC3GKMT2A
SCHEMBL923466 0.97 LMNA (0.57) BBOX1LMNAAPOBEC3AAPOBEC3GKMT2A
Bromide SCHEMBL7605138 0.97 BBOX1 (0.54) BBOX1LMNAAPOBEC3AAPOBEC3GKMT2A
SCHEMBL3037609 0.97 LMNA (0.57) BBOX1LMNAAPOBEC3AAPOBEC3GKMT2A
Water SCHEMBL29283573 0.97 BBOX1 (0.54) BBOX1LMNAAPOBEC3AAPOBEC3GKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3272740-A2 HIGH STABILITY DIIONIC LIQUID SALTS Sigma-Aldrich Co. LLC (US) 2018-01-24 EP disclosed
EP-3272740-A2 HIGH STABILITY DIIONIC LIQUID SALTS Sigma-Aldrich Co. LLC (US) 2018-01-24 EP disclosed
US-9782746-B2 Polymeric ionic liquids, methods of making and methods of use thereof THE UNIVERSITY OF TOLEDO (US) 2017-10-10 US disclosed
US-20160114309-A1 Polymeric Ionic Liquids, Methods of Making and Methods of Use Thereof THE UNIVERSITY OF TOLEDO (US) 2016-04-28 US disclosed
US-9249261-B2 Polymeric ionic liquids, methods of making and methods of use thereof THE UNIVERSITY OF TOLEDO (US) 2016-02-02 US disclosed
US-8956445-B2 High stability diionic liquid salts SIGMA-ALDRICH CO. (US) 2015-02-17 US disclosed
US-8734673-B2 Boron selective ionic liquids and polymeric ionic liquids, methods of making and methods of use thereof THE UNIVERSITY OF TOLEDO (US) 2014-05-27 US disclosed
US-20140121387-A1 High Stability Diionic Liquid Salts SIGMA-ALDRICH CO. LLC (US) 2014-05-01 US disclosed
US-20140121387-A1 High Stability Diionic Liquid Salts SIGMA-ALDRICH CO. LLC (US) 2014-05-01 US disclosed
EP-2682396-A1 High stability diionic liquid salts Sigma-Aldrich Co. (US) 2014-01-08 EP disclosed
US-8182581-B2 use of these novel bis-cationic and/or bis-anionic ionic liquids as the stationary phase in a gas chromatographic column SIGMA-ALDRICH CO. LLC (US) 2012-05-22 US disclosed
US-20120111796-A1 Boron Selective Ionic Liquids and Polymeric Ionic Liquids, Methods of Making and Methods of Use Thereof UNIVERSITY OF TOLEDO (US) 2012-05-10 US disclosed
US-8168830-B2 use of these novel ionic liquids having bis-cation or bis-anion separated by bridging group as the stationary phase in a gas chromatographic column SIGMA-ALDRICH CO. LLC (US) 2012-05-01 US disclosed
US-8168830-B2 use of these novel ionic liquids having bis-cation or bis-anion separated by bridging group as the stationary phase in a gas chromatographic column SIGMA-ALDRICH CO. LLC (US) 2012-05-01 US disclosed
US-20110236295-A1 Polymeric Ionic Liquids, Methods of Making and Methods of Use Thereof UNIVERSITY OF TOLEDO (US) 2011-09-29 US disclosed
WO-2010017563-A1 POLYMERIC IONIC LIQUIDS, METHODS OF MAKING AND METHODS OF USE THEREOF UNIVERSITY OF TOLEDO (US) 2010-02-11 WO disclosed
WO-2010017564-A1 BORON SELECTIVE IONIC LIQUIDS AND POLYMERIC IONIC LIQUIDS, METHODS OF MAKING AND METHODS OF USE THEREOF UNIVERSITY OF TOLEDO (US) 2010-02-11 WO disclosed
US-20080027231-A1 High stability diionic liquid salts SIGMA-ALDRICH CO. (US) 2008-01-31 US disclosed
US-20080027231-A1 High stability diionic liquid salts SIGMA-ALDRICH CO. (US) 2008-01-31 US disclosed
US-20060025598-A1 High stability diionic liquid salts ADVANCED SEPARATION TECHNOLOGIES INC. (US) 2006-02-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080027231-A1 High stability diionic liquid salts H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, HDHD5, DAD1 BBOX1 4134/4885LMNA 739/4885APOBEC3A 2403/4885
US-20060025598-A1 High stability diionic liquid salts H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, DCLK2, HDHD5 BBOX1 4186/4885LMNA 671/4885APOBEC3A 2434/4885
US-20120111796-A1 Boron Selective Ionic Liquids and Polymeric Ionic Liquids, Methods of Making and Methods of Use Thereof BCCIP, SLC6A12, BOLA2; BOLA2B BBOX1 446/4885LMNA 584/4885APOBEC3A 291/4885
US-20140121387-A1 High Stability Diionic Liquid Salts H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, DCLK2, HDHD5 BBOX1 4186/4885LMNA 671/4885APOBEC3A 2434/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.